Uludag Mehmet, Unlu Mehmet Taner, Kostek Mehmet, Aygun Nurcihan, Caliskan Ozan, Ozel Alper, Isgor Adnan
Division of Endocrine Surgery, Department of General Surgery, University of Health Sciences Türkiye, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Türkiye.
Department of Radiology, University of Health Sciences Türkiye, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Türkiye.
Sisli Etfal Hastan Tip Bul. 2023 Sep 29;57(3):287-304. doi: 10.14744/SEMB.2023.06992. eCollection 2023.
Thyroid nodules are common and the prevalence varies between 4 and 7% by palpation and 19-68% by high-resolution USG. Most thyroid nodules are benign, and the malignancy rate varies between 7 and 15% of patients. Thyroid nodules are detected incidentally during clinical examination or, more often, during imaging studies performed for another reason. All detected thyroid nodules should be evaluated clinically. The main test in evaluating thyroid function is thyroid stimulating hormone (TSH). If the serum TSH level is below the normal reference range, a radionuclide thyroid scan should be performed to determine whether the nodule is hyperfunctioning. If the serum TSH level is normal or high, ultrasonography (US) should be performed to evaluate the nodule. US is the most sensitive imaging method in the evaluation of thyroid nodules. Computed tomography (CT) and magnetic resonance imaging are not routinely used in the initial evaluation of thyroid nodules. There are many risk classification systems according to the USG characteristics of thyroid nodules, and the most widely used in clinical practice are the American Thyroid Association guideline and the American College of Radiology Thyroid Imaging Reporting and Data System. Fine needle aspiration biopsy (FNAB) is the gold standard method in the evaluation of nodules with indication according to USG risk class. In the cytological evaluation of FNAB, the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is the most frequently applied cytological classification. TBSRTC is a simplified, 6-category reporting system and was updated in 2023. The application of molecular tests to FNAB specimens, especially those diagnosed with Bethesda III and IV, is increasing to reduce the need for diagnostic surgery. Especially in Bethesda III and IV nodules, different methods are applied in the treatment of nodules according to the malignancy risk of each category, these are follow-up, surgical treatment, radioactive iodine treatment, and non-surgical ablation methods.
甲状腺结节很常见,触诊患病率在4%至7%之间,高分辨率超声检查(USG)的患病率在19%至68%之间。大多数甲状腺结节是良性的,恶性率在患者中为7%至15%。甲状腺结节在临床检查期间偶然发现,或者更常见的是在因其他原因进行的影像学检查中发现。所有检测到的甲状腺结节都应进行临床评估。评估甲状腺功能的主要检查是促甲状腺激素(TSH)。如果血清TSH水平低于正常参考范围,应进行放射性核素甲状腺扫描以确定结节是否功能亢进。如果血清TSH水平正常或升高,应进行超声检查(US)以评估结节。US是评估甲状腺结节最敏感的影像学方法。计算机断层扫描(CT)和磁共振成像在甲状腺结节的初始评估中不常规使用。根据甲状腺结节的USG特征有许多风险分类系统,临床实践中使用最广泛的是美国甲状腺协会指南和美国放射学会甲状腺影像报告和数据系统。细针穿刺活检(FNAB)是根据USG风险类别对有指征的结节进行评估的金标准方法。在FNAB的细胞学评估中,甲状腺细胞病理学报告贝塞斯达系统(TBSRTC)是最常用的细胞学分类。TBSRTC是一个简化的6类报告系统,于2023年更新。对FNAB标本应用分子检测,尤其是那些诊断为贝塞斯达III类和IV类的标本,正在增加,以减少诊断性手术的需求。特别是在贝塞斯达III类和IV类结节中,根据每个类别的恶性风险对结节采用不同的治疗方法,这些方法包括随访、手术治疗、放射性碘治疗和非手术消融方法。